Bayer Signs Grant Agreement to Advance Research in Non-Hormonal ContraceptionBusiness Wire • 11/08/22
Outside the US Bayer Extends Development Program for Investigational Product Elinzanetant With Phase III Study in Breast Cancer Patients With Vasomotor Symptoms Caused by Endocrine TherapyBusiness Wire • 11/07/22
Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology's 2022 Kidney WeekBusiness Wire • 11/02/22
Bayer's KERENDIA® (finerenone) Recommended as Part of Comprehensive Treatment Strategy for Chronic Kidney Disease Associated With Type 2 Diabetes in Newly Published Clinical RecommendationsBusiness Wire • 10/27/22
Nori Partners With Bayer's ForGround Platform to Scale Its Carbon Marketplace Through Verified Carbon RemovalsBusiness Wire • 10/24/22
Bayer's KERENDIA® (finerenone) Receives Grade A Recommendation as Treatment Option for Patients With Chronic Kidney Disease Associated With Type 2 Diabetes in Latest Guideline Update From American Association of Clinical EndocrinologyBusiness Wire • 10/10/22
Bayer Completes Sale of Its Environmental Science Professional Business to CinvenBusiness Wire • 10/05/22
Bayer Fund Announces $8.2M in Donations to U.S. Nonprofit Organizations During First Half of 2022Business Wire • 09/28/22
Bayer Announces Further Investment in Direct Relief Community Health Awards ProgramBusiness Wire • 09/26/22
Bayer's KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 DiabetesBusiness Wire • 09/01/22